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Previous comparisons between presenile Alzheimer’s disease (AD) and senile dementia of the Alzheimer type (SDAT) 
did not control for disease severity and duration. In the current study, 18 patients with each diagnosis were matched 
for disease duration, cognitive dysfunction, and behavioral symptoms (using the modified Mini-Mental Status 
{mMMS] examination and the Blessed Dementia Rating Scale {BDRS}). Regional cerebral blood flow (KBF) was 
quantified by the i33xenon inhalation technique, and several indices of tissue perfusion were examined. The two 
variables of primary interest were relative gray-matter weight and a gray-matter perfusion index, the initiai slope 
index. Presenile onset was associated with loss of gray-matter relative weight (35% in presenile patients versus 39% in 
senile patients and healthy control subjects,p = 0.006), with neither perfusion nor disease severity differences between 
the two dementia samples. This loss of gray matter was significantly related to both severity and duration of disease in 
the patients with presenile AD, but not in patients with SDAT. These findings lend support to previous suggestions of 
greater degenerative process in presenile AD and confirm the need to examine and control age of onset in future 
investigations of AD. Further, correlation analysis suggests greater proportion of common variance among clinical and 
physiological indices in presenile AD. 
Prohovnik I, Smith G, Sackeim HA, Mayeux R, Stern Y. Gray-matter degeneration 
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Age at onset (AAO) of Alzheimer’s disease (AD) may 
predict course and severity of the disease, but previous 
reports show iittle consensus on this point [i-41. Most 
previous studies have suggested more severe disease 
manifestations associated with earlier onset. The Com- 
mission on Nosology, Epidemiology, Etiology and 
Pathophysiology 151, recogniting the similarity of clini- 
cal and pathological manifestations and the possibility 
of different causes, recommended the terms Alz- 
heim8s disease for presenile onset and senile dementia of 
the Alzheimer type (SDAT) for senile onset. 
Differences between the presenile and senile vari- 
ants may reflect fundamental pathophysiological pro- 
cesses or may be a function of varying disease severity 
and rate of progression. For instance, if earlier onset is 
associated with more rapid progression, such patients 
may present with more severe degeneration and symp- 
tomatology at a given duration from diagnosis. This 
study is the first to compare presenile and senile onset 
patients matched for duration of disease as well as for 
symptomatic severity. 
Measurements of regional cerebral blood flow 
(rCBF) appear to provide a sensitive, specific, and reli- 
able marker of AD, even at early stages [6,7]. The 
largest study to date that examined rCBF in presenile 
and senile patients [b] reported subtle relative differ- 
ences in regional cerebral perfusion but failed to con- 
trol for severity. We here report the first investigation 
of AAO effects on CBF in early-stage AD, with strict 
control of severity of disease. Further, the study by 
Risberg and Gustafson [Gf examined only one variable, 
the initial slope index (ISI), which is dominated by 
gray-matter perfusion. We report that the major AAO 
effect involves reduction of apparent gray-matter 
weight in presenile onset patients. 
Methods 
Subjects 
Patients with clinically diagnosed AD in a community-based 
memory disorders clinic were eligible. We selected only pa- 
tients who fulfilled NINCDS-ADRDA criteria 171. We fur- 
ther selected patients with presenile and senile onset (less 
than 65 or 65 and greater) to yield sample means matched 
for severity. This was done because in our larger, unselected 
samples, presenile patients were more severely impaired. 
The analysis includes 36 patients with early AD, 18 of pre- 
senile onset, and 18 of senile onset. Table 1 provides a de- 
tailed list of their characteristics. Mean duration of disease in 
al1 AD patients was 3.25 I 1.80 years, and there were no 
significant differences in disease severity between the two 
AAO subgroups. They differed significantly, as expected, in 
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Table I. Sample Cbaracterization Table 2. Mean Cwebral Perfusion Variablesa 
Mean (SD) Mean 2 SD 
Presenile Senile 
Variable (n = 18) (n = 18) P" 
Age 60.22 (4.91) 76.00 (4.88) 0.001 
AAO 56.67 (4.82) 72.61 (4.10) 0.001 
Durationb 3.56 (1.67) 2.94 (1.87) 0.322 
mMMS 27.89 (14.92) 32.11 (14.14) 0.403 
BDRS 8.62 (3.50) 9.39 (4.04) 0.563 
PeC02 38.91 (4.34) 38.61 (2.77) 0.806 
Systolic BP 126.73 (20.84) 147.88 (19.78) 0.008 
Diastolic BP 81.47 (12.50) 82.53 (12.24) 0.641 
Hemoglobin 13.95 (1.26) 14.74 (1.10) 0.071 
"Unpaired t tests, two-tailed. 
bClinically assessed, in years. 
AAO = age at onset; mMMS = modified Mini-Mental StaNS Ex- 
amination; BDRS = Blessed Dementia Rating Scale; PeC02 = 
end-tidal determinations of COz partial pressure; BP = blood pres- 
sure. 
age and AAO. Thirty patients were dnig free for at least 1 
month; the other 6 were being treated with neuroleptic 
agents, coronary agents, methenamine mandelate, and chlor- 
propamide. There was no relation between AAO and medi- 
cation status. 
Twelve healthy elderly subjects were compared as control 
subjects. These subjects had no history of psychiatric or 
neurological disease and a mean age of 63.25 2 8.11. They 
were recruited by advertising in community newspapers. 
Diagnostic and Severity Measures 
Patients were diagnosed by clinical criteria prior to other 
procedures. They underwent a physical and neurological ex- 
amination, computed tomographic (CT) scan, blood workup 
(SMA 12), neuropsychological test battery, and electroen- 
cephalogram (EEG). 
The two AD subsamples were matched on three dimen- 
sions: (1) estimated duration of the disease, (2) cognitive 
deficits, and (3) functional capacity. Duration was clinically 
assessed by interviewing patients and family members. 
Global cognitive deficit was quantified with the MMS (Mini- 
Mental Status examination [8]), as modified by Mayeux and 
colleagues [9] (here called mMMS). Functional capacity was 
assessed by the Blessed Dementia Rating Scale (BDRS) 
[io]. The majority of patients can be described as mildly 
demented (CDR 1 by the Berg and coworkers 11 11 criteria). 
rCBF Procedures 
rCBF was measured with a commerciai system (Novo Cere- 
brograph 32c, Scan Detectronic A / S ,  Hadsund, Denmark), 
using 16 detectors covering each hemisphere. Detector 
placement reproducibility was achieved by means of light 
markers aligned with the auditory meatus and the orbito- 
meatal line. Extensive quality control measures were em- 
ployed as detailed elsewhere [12). These included careful 
documentation of xenon dosage and various computerized 
goodness-of-fit tests, as well as visual examination of clear- 
ance curves and their computed solutions. Two clearance 
Variable Presenile Senile Pb 
M1 
ISI 44.43 7.13 46.85 6.10 
wt? 0.356 0.054 0.394 0.031 
ISI 39.99 6.33 41.88 5.75 
CBFI5 31.51 4.32 34.19 4.43 
f, 54.25 8.27 53.96 8.14 
k2 0.093 0.013 0.102 0.016 
0.352 0.050 0.395 0.025 wg 
M2 
"See Data Analysis secuon for definitions. 








curves (both in the anterior temporal pole) from 1 patient 
were excluded from analysis due to unsatisfactory quality. 
Al1 procedures were performed with the patient's eyes 
closed and covered in a darkened and relatively silent room. 
Sedation was not employed: ail patients could tolerate the 
procedure without medication. 
Data Analysis 
Clearance curves were analyted by a six-unknown model 
(here termed M2), which yields more accurate results under 
low-flow conditions, as expected here [13-151, as well as the 
four-unknown model I161 (here caiied Ml). Both models 
were used on 11 minutes of clearance monitoring. The M1 
model was used only to confirm the findings: in al1 instances, 
results were qualitatively similar but quantitatively more 
significant with the M2 model. Most results below pertain to 
the more powerful M2 model; Table 2 also provides data 
from the standard M1 model for validation and comparison 
purposes. 
The primary variables obtained from each model are p and 
k values for two parenchymal compartments, representing 
size and clearance rates; many secondary parameters can be 
derived from them. We routinely compute 17 primary and 
secondary variables from both models. The most sensitive 
and physiologically meaningful expression of corrical gray- 
matter perfusion is the flow gray (f,) quantified in nV1001 
&minute. However, it is known to suffer from lower reli- 
ability in low-flow conditions when compartmental distri- 
butions may be unstable, and therefore we use the initial 
slope index [15, 171 (ISI), which is more reliable and mostly 
influenced by gray-matter flow. 
Relative weight of gray matter (wg) was also derived [18}. 
It must be emphasized that the rCBF technique used here 
provides no anatomical specificity, and the term gray-mattw 
relative weigbt is inferential. Strictly speaking, this is the rela- 
tive weight of the fast-clearing companment. This does cor- 
respond to gray matter in the normal brain, and the perfu- 
sion differences between gray and white matter are so robust 
that this distinction is rarely lost. In a demented population, 
however, due to the low flows, a bicomparunental solution 
was not always obtained. Such monoexponential solutions 
yield a reliable ISI value, but no relative weight term and no 
white-matter clearance (k2). These curves were considered 
missing data for the wg and k2 analyses. Of the total of 1,152 
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clearance curves obtained in the demented patients, 17 
(1.5%) curves from 13 detector locations were monoexpo- 
nential; no one detector showed a significant preponderance 
of monoexponentiai solutions, nor was there a difference 
between presenile and senile patients (10 and 7 monoexpo- 
nential solutions, respectively). There were no missing data 
for whole-cortex means, and al1 ce11 sizes were complete. 
Global and regional differences between AD patients and 
heaithy control subjects were recently detailed elsewhere 
{7); the present communication addresses AAO effects 
within the dementia sample. Therefore, major analyses were 
conducted between the presenile and senile onset groups. 
Results 
Whole-Brain Values 
For both M 1 and M2 models, whole-brain mean perfu- 
sion did not differ significantly between the two de- 
mentia samples. Both samples had significantly lower 
perfusion than the normai sample. The purest gray- 
matter perfusion variable, f,, showed identical values 
for presenile and senile AD samples. ISI was slightly 
lower in the presenile sample, and k2 and CBFI5 were 
marginally significant ( p  = 0.07), lower in the pre- 
senile patients. However, w, showed substantial and 
significant reductions in the presenile patients. 
An analysis of variance, with w, as the dependent 
variable and diagnosis (control subjects, presenile, and 
senile groups) as a grouping factor, demonstrated 
significant differences (F2.45 = 5.83, p = 0.006). Post- 
hoc t tests showed that the presenile sample was 
significantly lower than both the normal (t28 = 2.37, 
p = 0.025) and senile (t34 = 3.14, p = 0.004) 
groups. Data are provided in Table 2,  and the bivari- 
ate discrimination of the three samples is depicted in 
Figure 1. 
Regional Dzfferences 
The demented patients, as a whole, showed a strikingly 
different regional pattern of flow, compared to the 
control subjects. As expected 171, they demonstrated 
reductions in parietal and frontal association areas with 
relatively preserved occipital and perirolandic perfu- 
sion. However, no significant differences in regional 
flow distribution were found between the two demen- 
tia subsamples. 
The differences in relative gray-matter weight be- 
tween the presenile and senile patients appeared dif- 
fuse. When each regional value was expressed as % of 
mean, Bonferroni-corrected t vaiues were not sig- 
nificant for any region. 
Cowekztions of Global Values 
Correlation matrices (Pearson product-moment coeffi- 
cients) were computed among the following variables: 
age, age at onset, duration of disease, mMMS, BDRS, 
and giobal means of ISI and wg; this was done within 
the totai dementia sample and within each subsample. 
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Fig I. Mean gray-matter perfusion and rekative weight 
(* SEM) in patients with presenile and senile onset Alz- 
heàmer's disease (AD) (n  = 18 each) compared with that of 
healthy elderly controlsubjects (n  = 12). Both AD samples 
shw redivcedpe$usion, but only presenile onset is associated 
with loss of relative gray-matter weight. 
Correlations for the total dementia sample were pre- 
viously discussed 171. ISI was significantly correlated 
with wg (r  = 0.51, p < 0.01); w, showed significant 
correlations with age (r = 0.49, p < O.Ol), age at onset 
(r = 0.53, p < O.OOl), and mMMS (r  = 0.386, p < 
0.05). In ai1 three, age and age at onset were aimost 
perfectly correlated (0.92 to 0.98). Also in al1 three 
groups, there were significant correlations between the 
mMMS and BDRS (-0.57 to -0.81), reflecting the 
common variance between cognitive deficits and hnc- 
tional incapacitation. 
Of note, the correlations appeared to be different 
between the two AAO subsamples. As Table 3 shows, 
all variables showed more powerful relationships 
within the presenile sample than within the senile sam- 
ple. Not only was wg better correlated to clinicai vari- 
ables in the presenile sample, but also the correlations 
among AAO, illness duration, BDRS, and mMMS 
were all significant for the presenile patients, whereas 
only the relationship between mMMS and BDRS was 
significant for the senile patients. Gray-matter weight 
was related to flow within the senile sample (r  = 0.47, 
p < 0.05), but not to any other variable. In contrast, 
within the presenile sample, w, was powerfdy related 
to flow (r = 0.55, p < 0.05), as well as to all three 
severity measures: duration (r  = -0.53, p < 0.05), 
mMMS (r = 0.48, p < 0.05), and BDRS (r = -0.50, 
p < 0.05), indicating loss of gray matter with greater 
disease severity. 
Interactions with Duration 
To assess possible interactions of AAO with estimated 
disease duration, all patients were divided into short 
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Table 3 .  Cowekztions Among Clinica1 Indices and L B F  Parameters" 
Age AAO Duration mMMS BDRS M2 ISI M2 wg 
AAO 0.92""" - 0.28 0.54" - 0.74'"" 0.39 0.36 
mMMS -0.38 -0.36 -0.14 - 0.8lXxx 0.30 0.48" 
M2 ISI 0.30 0.35 - 0.08 0.17 -0.19 0.55" 
M2 w, 0.2 1 0.12 0.26 0.18 0.09 0.47" 
Age 0.95""' 0.04 0.35 - 0.57* O. 36 0.20 
Duration 0.37 -0.01 - 0.61"' 0.64" -0.12 -0.53" 
BDRS 0.42 0.43 0.08 -0.57* -0.35 - 0.50" 
"Ali values represent the Pearson product-moment correlation coefficient. 
"p < 0.05. 
""p < 0.01. 
***p < 0.001. 
rCBF = regional cerebral blood flow; AAO = age at onset; mMMS = rnodified Mini-Mental Status Examination; BDRS = Blessed Dementia 
Rating Scale; M2 = six-unknown model; ISI = initial slope index; wg = relative gray-matter weight. 
Table 4. Short- and Long-Duration SampleJ 
Mean * SD 
Variable Short-Duration Long-Duration Difference" interactionb 
AAO 66.68 8.76 62.82 10.45 ns ns 
Duration 1.74 0.73 4.94 0.97 < 0.001 ns 
mMMS 36.11 10.26 23.18 16.53 0.007 ns 
BDRS 7.90 4.07 10.34 3.22 ns ns 
M2 ISI 41.49 5.77 41.16 6.37 ns ns 
M2 wg 0.386 0.035 0.358 0.050 ns 0.03 1 
"Independent t test between the short and long duration samples, p value. 
bInteraction between duration and AAO, two-way ANOVA, p value. 
ns = not significant; other abbreviations are the same as in Table 3 .  
duration (n = 19, 11 senile and 8 presenile onset) and 
relatively long duration (n = 17, 7 senile and 10 pre- 
senile onset); short duration was defined as 3 years or 
less. Two-way ANOVAs were then conducted to as- 
sess the effects of AAO, duration, and their interac- 
tion. These samples are characterized in Table 4 .  
Mean duration of illness in the two samples was 
about 2 versus 5 years. As expected, the short- 
duration sample was less cognitively impaired ( p  = 
0.007) and rated less severely on the BDRS ( p  = 
0.06). Cerebral perfiusion was identical in the two sam- 
ples, and wg was not significantly lower in the long- 
duration sample. Gray-matter weight was significantly 
associated with AAO (F1.32 = 11.67, p = 0.002), as 
expected, but there was also a significant interaction 
with duration (F1.32  = 5.17, p = 0.03). This interac- 
tion is illustrated in Figure 2 ,  showing that at short 
durations the two dementia samples were similar, 
whereas at longer durations wg was reduced in the 
presenile sample only. 
Discussion 
Previous work suggested that a more virulent disease 
process is associated with an earlier onset of AD. On 
neuropathological examination, presenile onset pa- 
tients manifest greater densities of senile plaques, 
neurofibrillary tangles, celi loss, and choline acetyl- 
transferase (ChAT) depletion 119-221. Greater cogni- 
tive and behavioral deficits 119, 231, biochemical ab- 
normaiities 124, 251, and shorter life expectancy 141 
have also been reported in the younger presenile 
patients. 
It is unclear whether AAO predicts the course of 
Alzheimer's disease or its pathophysiology, indepen- 
dently of severity. If, as suggested, presenile onset is 
associated with greater behavioral severity or a more 
rapid progression, then a comparison of senile and pre- 
senile patients may yield differences attributable sim- 
ply to the greater severity of the presenile variant. To 
determine whether presenile onset is associated with a 
fundamentally different process, severity of disease 
must be controlled, and duration of disease may not 
suffice if rates of progression confound the severity 
findings. This distinction has not, to our knowledge, 
been made in previous studies. 
Our samples were selected so as to minimize this 
bias: senile and presenile patients had the same dura- 
tion of disease, cognitive impairments, and functional 
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Fig  2. Relative gray-matter weight (I SEM) by age of onset as 
wellas duration of Alzheimer’s disease (AD). SP = short-dura- 
tion, presenile; LP = long-duration, presenile; SS = short-dura- 
tion, senile; LS = long-duration senile. A significant reduction 
dgray-mutter weight was found only for patients with presenile 
onset and reiatiuely long daration of disease. 
capacity. Our results suggest, therefore, that even 
when duration and severity are equal, there is greater 
loss of gray matter with presenile onset. One could 
argue, if the hypothesis of greater severity in presenile 
onset is accepted, that our matched samples represent 
atypical patients. Even in that case, however, the cur- 
rent results demonstrate that presenile onset, per se, is 
associated with greater atrophy without the necessary 
concomitant of symptomatic severity. 
Some corroboration for greater cerebral atrophy in 
presenile onset can be found in the literature. Kohl- 
meyer and Shamena 126) reported greater cortical at- 
rophy in computed tomographic (CT) scans of pre- 
senile AD patients than in those with SDAT, and 
Albert and colleagues 1271 found similar differences in 
CT density measurements. This loss of tissue raises 
questions regarding the vaiidity of flow and metabo- 
iism determinations. Findings by positron emission to- 
mography (PET) and single-photon emission com- 
puted tomography methods, using tracer trapping and 
distribution models rather than clearance, have been 
questioned with regard to the effect of atrophy: the 
reduction of Aow or metabolism may be an artifactual 
consequence of loss of nerve tissue, despite normal 
function of the remaining viable tissue 128). Moroi and 
coworkers 1291 reported that metabolic PET images 
are distorted by atrophy, but the distortion does not 
substantiaily alter the typical findings of temporo- 
parietal deficits. Xenon, however, providing dynamic 
clearance data, yields flow results in d 1 0 0  &minute 
which are independent of tissue volume. The loss of 
gray matter we found suggests that PET studies not 
corrected for atrophy may indeed find artifactually low 
flow and metabolism in presenile AD. 
In this article, we describe a functional loss of gray 
matter: the amount of tissue perfused at typical gray 
matter levels is reduced in presenile patients whose 
disease is of relatively long duration. This observation 
was not made in the three previous studies of wg in 
AD. A reduction of wg in SDAT patients (presenile 
patients were not examined) was recently reported by 
Deutch and Tweedy 1301, but these authors did not 
exclude monoexponential solutions that yielded wg = 
O, resulting in low means and high variance. Their pa- 
tients were not characterized by a standard clinical 
scale, but the very low perfusion values would suggest 
severe impairment, In fact, the authors used M1 ISI 5 
30 to differentiate SDAT patients; this perfusion leve1 
was completely absent in our sample of 36 mild AD 
patients, and only 1 patient had M1 ISI between 30 
and 35. Obrist and associates 131) examined 10 pa- 
tients with “senile dementia” and 8 with “presenile 
dementia.” Both dementia samples demonstrated 
significantiy lower values of mean tissue perfusion, 
gray-matter perfusion, and wg; the presenile, but not 
senile, patients also showed reductions of white-matter 
perfusion similar to our findings. These authors also 
reported correlations of rCBF results with severity 
rankings. The reasons for the lack of wg differences 
due to AAO in this study are unclear, but both clinical 
methodology and rCBF technology were not compara- 
ble to ours. Other findings are also inconsistent: Obrist 
and associates 131) found focal deficits in frontotem- 
poral regions, whereas current consensus impiicates 
parietotemporal regions 17). 
Whether the wg reduction reflects actual loss of 
neurons, known to occur in AD 1321, or only a re- 
duced function to white-matter levels remains to be 
rigorously established. Gray-matter tissue may be per- 
fused at white-matter levels without permanently los- 
ing viability 1331, and the findings reported here do 
not necessarily imply irreversible tissue damage. Al- 
though the wg term represents gray-matter weight only 
inferentially (strictly speaking, we have found loss of 
“fast-clearing compartment” in the presenile AD 
cases), this compartment does represent gray matter in 
the normal brain, and it is established that no white 
matter achieves clearance rates comparable to gray 
matter r341. Second, because the term represents rela- 
tive weight only, in relation to total tissue observed, 
the results could be interpreted as “gin” of white mat- 
ter or &ai ceiis. This is highly improbabie: although 
Brun and Englund E351 reported a mild reactive astro- 
cytic gliosis in AD, their major finding was a loss of 
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white matter consistent with chronic hypoperfusion in 
about two-thirds of their patients. Findy, dissociations 
between flow and w, confirm our quality control mea- 
sures in suggesung the absence of “slippage” 1121 as a 
determinant of the observed w, differences. Slippage 
refers to a mathematical anifact caused by inadequate 
match between observed data and the physiological 
model; the most common variant yields overestimated 
flow and underestimated weight. If this occurred in the 
current material, w, reductions in the presenile sample 
should have been associated with higher flow values. 
In fact, the fs data demonstrate no differences between 
the samples. 
Of note, common slippage raises k2, in addition to 
fg Our data show lower k2 values in the presenile 
sample, as weli as reduced wg If presenile onset is 
associated with some portion of gray matter being per- 
fused at very low levels approaching white-matter flow, 
but no absolute loss of perfused tissue, k2 should be 
elevated as weli as p2. In fact, k2 was lower in presenile 
patients and p2 showed no difference. Considering the 
distributions proposed by Reivich and colleagues 1341, 
the combined observations of unchanged fg, lower k2. 
and lower wg may indicate a loss, rather than a shift, 
of gray matter. Older literature appears to be consis- 
tent with this interpretation. Hgedt-Rasmussen and 
SkinhGj {361, using intracarotid administration of 
133xenon, reported a mean w, of 48.8 i 4.5% in un- 
characterized normal subjects. The value dropped to 
38.9 ? 8.0% in 8 patients with “degenerative brain 
disease.” In addition, the authors suggested that there 
was a further decline of wg in the presence of severe 
dementia or severe cerebral atrophy (as visuaiized by 
pneumoencephalography). Unfortunately, neither the 
patients nor the control subjects were characterized. 
Of major relevance, however, are the reported validity 
tests. HGedt-Rasmussen and Skinhoj reported an ex- 
cellent correlation between xenon uptake and known 
distributions of gray and white matter in vitro, and no 
correlation between perfusion rate and ws estimates in 
vivo. The relationship observed with atrophy also sug- 
gested that the w, index was a valid measure of tissue 
loss. We therefore propose that there is actual tissue 
destruction in presenile AD, although the evidence at 
present is inconclusive. 
In addition to differences in mean values, the pat- 
tern of w, correlations showed dissimilarities between 
the presenile and senile subsamples. In the presenile 
patients, wg was significantly predicted by al1 three se- 
verity dimensions, with a total multiple regression of 
0.57: 32% of wg variance is thus predicted by severity. 
In contrast, no significant correlations were observed 
in the senile sample. It appears, thus, that in presenile 
AD this loss is related to the duration and severity of 
the disease, possibly with causa1 significance. 
Within both samples there was a significant positive 
correlation between perfusion and wg This positive 
relationship was expected: the ISI represents perfusion 
in both gray and white matter, and a deciine in the 
relative amount of fast-clearing tissue must reduce the 
ISI value. In several other respects, the ws findings are 
dissociated from perfusion abnormalities. As Figure i 
depicts, there were no differences in gray-matter blood 
flow between the two dementia subsamples (globally 
or regionally), and both were significantly reduced in 
this respect from normal values. Gray-matter weight 
was reduced only in the presenile sample, and it dif- 
fered significantly from both control and senile values. 
Such dissociation between w, and perfusion was aìso 
evident when duration effects were examined (see 
Table 4) .  Further, the correlations between w, and du- 
ration and severity within the presenile sample were ali 
significant, whereas none of these correlations was 
significant with flow. Finally, whereas the perfusion dif- 
ferences between demented patients and control sub- 
jects show a sharp regional pattern 171, the wg reduc- 
tion in presenile onset was diffuse. 
It appears, therefore, that the process associated 
with loss of gray matter in presenile AD teads to qual- 
itatively dissimilar phenomena from the process which 
causes a global and focai reduction of cerebral perfu- 
sion and metabolism in AD. This dissociation is remi- 
niscent of the sequelae of lesions in the nucleus basalis 
of Meynert (NbM) in animal models: recovery of 
memory functions and cerebral glucose utilization oc- 
cur despite persistent ChAT deficits and cell loss {37, 
381. Similarly, Neary and colleagues 1391 have shown 
in 17 presenile AD patients that severity of dementia 
was correlated with loss of large cortical neurons but 
not with reduction in ChAT activity. 
It is reasonable, therefore, to hypothesize that there 
are two processes in AD. Cerebral perfusion is associ- 
ated with the disease, possibly through cholinergic 
mechanisms, and perfusion abnormalities are not a 
function of age at onset, similarly to the recently re- 
ported elevation of membrane fluidity 1401. Structural 
damage to cortical tissue is dissociated from perfusion 
deficit both in the NbM model and in our findings, 
where it is associated with earlier onset and greater 
symptomatic severity. Presenile onset of AD entails 
relative loss of cerebral gray matter, proportiond to 
symptomatic severity and duration, but such loss is not 
seen following senile onset, with similar duration, se- 
verity, and perfusion deficits. Perfusion abnormalities 
are independent of age at onset and may represent 
more a threshold phenomenon than a graduai worsen- 
ing, because they appear with full magnitude even in 
very miidiy impaired patients [7}. 
The differences between the current two AAO sam- 
ples extended also to the clinical indices. Although 
they were matched on illness duration and two severity 
scales, the relationships among those indices were dif- 
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ferent: mMMS and BDRS were related to AAO and 
illness duration in the presenile patients, but not within 
the senile-onset patients. The same was true for the 
loss of gray matter: whereas at short durations the sam- 
ples are simiiar in wg, longer durations are associated 
with lower wg in the presenile, but not senile, patients. 
Although interpretation of these observations must 
await replication, they indicate further fundamentai 
differences between the two disease variants. With 
presenile onset, there is a greater proponion of com- 
mon variance among the clinicai indices as well as re- 
lated loss of gray matter. 
We conclude that in the early stages of presenile 
AD, but not in A D  of senile onset, there is a loss of 
conicai gray matter, even when the two samples are 
carefuily matched for duration and severity of disease. 
This loss of gray matter is diffuse, and unaccompanied 
by perfusion differences, suggesting that the remaining 
viable tissue functions at similar metabolic leveis. This 
loss of gray matter is related to duration and symptom- 
atic severity in presenile AD, indicating a fundamental 
relationship to the disease process that is not apparent 
in senile-onset patients. Further, the correlationai 
structure of severity and duration variables appears to 
indicate a substantiai common variance in presenile, 
but not senile, patients. Gray-matter perfusion abnor- 
maiities are aiso evident in the early stages of the dis- 
ease, but they are identical in presenile and senile on- 
set patients. 
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